When targeting APP in the course of therapeutic intervention for AD, or APLP1 to inhibit α-synuclein propagation in Parkinson’s Disease, it will therefore be crucial to avoid compromising shared physiological functions within the APP family. This evidence concerns the gene APLP1 and Parkinson disease.